Analyze the relationships between the prevalence of the clinical sign follicular trachoma (TF) and the prevalence of infection and antibody to determine whether it may be appropriate to consider one or more alternative indicators for deciding whether trachoma programs can stop MDA.
Exploring alternative indicators for trachoma endpoint decision-making (Tanzania)
Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool for National Trachoma Control Programs? Results from a District Survey
Sheila K. West, Beatriz Munoz, Jerusha Weaver, Zakayo Mrango, Laura Dize, Charlotte Gaydos, Thomas C. Quinn, and Diana L. Martin
Email primary contact
Please log in or register